Squire Patton Boggs has announced the addition of Delia Deschaine as a partner in its global corporate practice, significantly enhancing the firm’s capabilities in the healthcare and life sciences sectors. Deschaine, who brings extensive experience in advising pharmaceutical and biotechnology companies, joins the firm from Epstein Becker & Green. Her practice areas include Food and Drug Administration (FDA) and Drug Enforcement Administration (DEA) regulatory matters, transactional issues, and government investigations.
The firm’s statement on the matter highlights Deschaine’s expertise and how it aligns with Squire Patton Boggs’ strategic goals to bolster its healthcare and life sciences offerings. For more detailed information on the firm’s announcement, please visit Squire Patton Boggs’ official news release.
For legal professionals working in sectors impacted by FDA and DEA regulations, Deschaine’s move to Squire Patton Boggs may signal an increased focus on these areas within the firm, potentially opening new avenues for expertise and representation.
This development underscores a continuing trend where leading law firms are enhancing their regulatory and compliance practices amidst an evolving legal landscape. For further coverage of this story, refer to the report by Bloomberg Law.